The construction commencement ceremony for JOINN Laboratories and JOINN Biologics' project is held on June 28. [Photo/liangjiang.gov.cn]

JOINN Laboratories and JOINN Biologics, two Beijing-based medicine firms, started to construct their new project on June 28 in Shuitu New City, Liangjiang New Area, in Southwest China's Chongqing municipality.

Duan Chenggang, secretary of the Chongqing Liangjiang New Area Party Work Committee, and Luo Lin, deputy secretary of the Chongqing Liangjiang New Area Party Work Committee and director of the Chongqing Liangjiang New Area Administrative Committee, attended the project's commencement ceremony.

Feng Yuxia, president of JOINN Laboratories and JOINN Biologics, preferred Liangjiang for its complete infrastructure and preferential business environment.

Duan said the new project launched by the two companies will fill the gaps in Chongqing's macromolecular-drug research capabilities and is bound to facilitate the bio-medicine industry's technological innovation and high-quality development in Liangjiang New Area and Chongqing.

He hopes the two firms can further extend the industrial chain and lead the medicine industry, attracting more medicine corporations to come to Liangjiang.

Luo highlighted Liangjiang's role as a major growth pole and main arena for Chongqing's economic performance. The bio-medicine sector in the new area is expected to become an industry cluster with an annual output of some 100 billion yuan ($15 billion).

Currently, the new area prioritizes the innovation of the bio-medicine sector by collecting global high-end innovative resources, establishing platforms for technological innovations and optimizing the industrial structure.